[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA33604B1 - Composés et compositions en tant qu'inhibiteurs de protéine kinase - Google Patents

Composés et compositions en tant qu'inhibiteurs de protéine kinase

Info

Publication number
MA33604B1
MA33604B1 MA34716A MA34716A MA33604B1 MA 33604 B1 MA33604 B1 MA 33604B1 MA 34716 A MA34716 A MA 34716A MA 34716 A MA34716 A MA 34716A MA 33604 B1 MA33604 B1 MA 33604B1
Authority
MA
Morocco
Prior art keywords
formulations
components
protein kinase
kinase inhibitors
compounds
Prior art date
Application number
MA34716A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Shenlin Huang
Xianming Jin
Zuosheng Liu
Daniel Poon
John E Tellew
Yongqin Wan
Xing Wang
Yongping Xie
Original Assignee
Novartis Ag
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42782253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33604(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Irm Llc filed Critical Novartis Ag
Publication of MA33604B1 publication Critical patent/MA33604B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
MA34716A 2009-08-28 2012-03-23 Composés et compositions en tant qu'inhibiteurs de protéine kinase MA33604B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23807309P 2009-08-28 2009-08-28
US31303910P 2010-03-11 2010-03-11
PCT/US2010/046930 WO2011025927A1 (en) 2009-08-28 2010-08-27 Compounds and compositions as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
MA33604B1 true MA33604B1 (fr) 2012-09-01

Family

ID=42782253

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34716A MA33604B1 (fr) 2009-08-28 2012-03-23 Composés et compositions en tant qu'inhibiteurs de protéine kinase

Country Status (50)

Country Link
US (12) US8501758B2 (me)
EP (2) EP2470526B1 (me)
JP (2) JP5475888B2 (me)
KR (1) KR101413392B1 (me)
CN (2) CN103896921B (me)
AR (1) AR077975A1 (me)
AU (1) AU2010286569C1 (me)
BR (1) BR112012004453B1 (me)
CA (1) CA2771775C (me)
CL (1) CL2012000340A1 (me)
CO (1) CO6612222A2 (me)
CR (1) CR20120102A (me)
CU (1) CU24110B1 (me)
CY (3) CY1118452T1 (me)
DK (2) DK2470526T3 (me)
DO (1) DOP2012000051A (me)
EA (2) EA025222B1 (me)
EC (2) ECSP12011700A (me)
ES (2) ES2492499T3 (me)
GE (1) GEP20146102B (me)
GT (1) GT201200053A (me)
HK (1) HK1167390A1 (me)
HN (1) HN2012000441A (me)
HR (2) HRP20140799T1 (me)
HU (3) HUE032847T2 (me)
IL (1) IL218084A (me)
IN (1) IN2012DN02469A (me)
JO (1) JO3002B1 (me)
LT (3) LT2727918T (me)
LU (2) LUC00101I2 (me)
MA (1) MA33604B1 (me)
ME (2) ME02684B (me)
MX (1) MX2012002546A (me)
MY (1) MY156259A (me)
NI (1) NI201200029A (me)
NL (1) NL300973I2 (me)
NO (2) NO2019011I1 (me)
NZ (1) NZ598924A (me)
PE (1) PE20120861A1 (me)
PL (2) PL2470526T3 (me)
PT (2) PT2727918T (me)
RS (2) RS53489B1 (me)
SG (2) SG178351A1 (me)
SI (2) SI2727918T1 (me)
SM (3) SMT201700036T1 (me)
TN (1) TN2012000081A1 (me)
UA (1) UA112285C2 (me)
UY (1) UY32860A (me)
WO (1) WO2011025927A1 (me)
ZA (1) ZA201202020B (me)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
ES2576061T3 (es) 2010-02-25 2016-07-05 Dana-Farber Cancer Institute, Inc. Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
US8907270B2 (en) 2010-06-30 2014-12-09 Schlumberger Technology Corporation Method and apparatus for gain regulation in a gamma detector
CN108542906A (zh) * 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
MY172729A (en) 2011-11-23 2019-12-11 Array Biopharma Inc Pharmaceutical formulations
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN103159736B (zh) * 2011-12-10 2015-05-13 通化济达医药有限公司 取代的吡唑激酶抑制剂
WO2013096637A1 (en) * 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CA2864169A1 (en) 2012-03-28 2013-10-03 Caroline Emery C-raf mutants that confer resistance to raf inhibitors
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
IN2015DN00099A (me) 2012-07-18 2015-05-29 Univ Saint Louis
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
SG11201500321YA (en) * 2012-08-07 2015-04-29 Novartis Ag Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
KR20210108502A (ko) 2012-08-17 2021-09-02 에프. 호프만-라 로슈 아게 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
WO2014047330A1 (en) * 2012-09-19 2014-03-27 Jean-Michel Vernier Novel raf kinase inhibitors
AU2013343425A1 (en) * 2012-11-08 2015-06-11 Novartis Ag Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
MX2015013466A (es) * 2013-03-21 2016-06-21 Novartis Ag Terapia de combinacion que comprende un inhibidor deb-raf y un segundo inhibidor.
TWI634114B (zh) * 2013-05-08 2018-09-01 永恒生物科技公司 作為激酶抑制劑之呋喃酮化合物
WO2014194127A1 (en) 2013-05-30 2014-12-04 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
ES2909910T3 (es) * 2013-12-20 2022-05-10 Biomed Valley Discoveries Inc Tratamiento contra el cáncer usando combinaciones de inhibidores de ERK y RAF
MX2016008362A (es) * 2013-12-23 2016-09-08 Novartis Ag Combinaciones farmaceuticas.
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
DE102015103158A1 (de) 2014-03-04 2015-09-10 Bergische Universität Wuppertal Verbindungen für die Behandlung des Melanoms
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2015145388A2 (en) 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
US10428387B2 (en) 2014-05-16 2019-10-01 University Of Massachusetts Treating chronic myelogenous leukemia (CML)
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
US10167279B2 (en) * 2014-09-12 2019-01-01 Novartis Ag Compounds and compositions as RAF kinase inhibitors
JP6681905B2 (ja) 2014-09-13 2020-04-15 ノバルティス アーゲー Ａｌｋ阻害剤の併用療法
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
LT3370768T (lt) 2015-11-03 2022-05-25 Janssen Biotech, Inc. Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas
BR112018012138A2 (pt) 2015-12-17 2018-12-04 Novartis Ag moléculas de anticorpo para pd-1 e usos das mesmas
EP3294716B1 (en) 2015-12-30 2020-04-15 Saint Louis University Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
RU2615986C1 (ru) * 2016-02-25 2017-04-12 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения
KR102439911B1 (ko) 2016-06-03 2022-09-05 어레이 바이오파마 인크. 제약학적 복합제제
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018124001A1 (ja) 2016-12-27 2018-07-05 国立研究開発法人理化学研究所 Ｂｍｐシグナル阻害化合物
EP3579872A1 (en) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN107540699A (zh) * 2017-10-16 2018-01-05 康化（上海）新药研发有限公司 一种2‑氨基‑3‑氟吡啶‑4‑硼酸盐酸盐的合成方法
US11725185B2 (en) 2017-12-28 2023-08-15 University Of Houston System Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
JP7262843B2 (ja) * 2018-07-12 2023-04-24 深▲チェン▼市塔吉瑞生物医薬有限公司 ジアリールピラゾール化合物、該化合物を含む組成物およびその使用
WO2020124397A1 (en) * 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
EP3968995A1 (en) 2019-05-16 2022-03-23 Eli Lilly and Company Triple combination of an erk1/2 inhibitor with a braf inhibitor and an egfr inhibitor for use in the treatment of brafv600e colorectal cancer
CN114746419B (zh) 2019-12-05 2023-10-24 国家医疗保健研究所 N-(3-(5-(嘧啶-4-基)噻唑-4-基)苯基)磺酰胺化合物及其用作braf抑制剂的用途
EP4196228A1 (en) 2020-08-13 2023-06-21 Albert Einstein College of Medicine N-cyclyl-sulfonamides useful for inhibiting raf
MX2023003867A (es) 2020-10-05 2023-04-18 Pf Medicament Combinacion de encorafenib y binimetinib a manera de tratamiento adyuvante contra melanoma resecado en etapa ii.
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法
KR102699226B1 (ko) 2021-06-09 2024-08-27 에프. 호프만-라 로슈 아게 암 치료를 위한 병용요법
CN114557977A (zh) * 2022-02-16 2022-05-31 北京康立生医药技术开发有限公司 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2024163166A1 (en) * 2023-01-30 2024-08-08 5Metis, Inc. Boron containing compounds and their uses
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4104250A (en) * 1976-08-11 1978-08-01 Borg-Warner Corporation Flame-retardant polymers with 1,3,5-triazines having halo- and halo-aryl substitutents
JPS5475888A (en) 1977-11-29 1979-06-18 Jiyasuko Kk Surgical laser
EP0184384B1 (en) 1984-12-06 1989-08-02 Pfizer Inc. Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
CA2231050A1 (en) 1995-09-07 1997-03-13 Biovail International Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
WO1997044058A1 (en) 1996-05-23 1997-11-27 Applied Research Systems Ars Holding N.V. Compounds that inhibit the binding of raf-1 or 14-3-3 proteins to the beta chain of il-2 receptor, and pharmaceutical compositions containing same
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
TR200000235T2 (tr) 1997-05-22 2000-05-22 G.D. Searle &Co. p38 kinaz inhibitörleri olarak ikame edilmiş pirazoller.
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
CA2396380C (en) 1999-12-23 2015-04-21 David Hayes Improved pharmaceutical compositions for poorly soluble drugs
WO2002018654A1 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The University Of Arkansas Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CN100506224C (zh) 2001-10-25 2009-07-01 诺瓦提斯公司 包含选择性环加氧酶-2抑制剂的组合
JP4399265B2 (ja) 2001-12-21 2010-01-13 ヴァーナリス（ケンブリッジ）リミテッド ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用
CN101486682B (zh) 2002-03-13 2013-08-14 阵列生物制药公司 作为mek抑制剂的n3烷基化苯并咪唑衍生物
EA200600495A1 (ru) 2003-09-23 2006-10-27 Новартис Аг Комбинация ингибитора vegf рецептора с химиотерапевтическим агентом
WO2005047266A1 (en) 2003-11-14 2005-05-26 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
MXPA06007820A (es) 2004-01-09 2006-09-01 Novartis Ag Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina como inhibidores de igf-ir.
AR049511A1 (es) 2004-06-10 2006-08-09 Irm Llc Compuestos y composiciones como inhibidores de quinasa de proteina
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
RU2007138264A (ru) 2005-03-17 2009-09-10 Новартис АГ (CH) N-[3-(1-АМИНО-5,6,7,8-ТЕТРАГИДРО-2,4,4b-ТРИАЗАФЛУОРЕН-9-ИЛ)ФЕНИЛ]БЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИН/ТРЕОНИНКИНАЗ, ПРЕЖДЕ ВСЕГО КИНАЗ В-RAF
US20070099856A1 (en) 2005-05-13 2007-05-03 Gumerlock Paul H Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
WO2007021966A1 (en) 2005-08-12 2007-02-22 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate hsp90 activity
WO2007022956A2 (en) 2005-08-22 2007-03-01 Novartis Ag Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent
EP1917258A2 (en) 2005-08-26 2008-05-07 SmithKline Beecham Corporation Pyrimidinyl-pyrazole inhibitors of aurora kinases
PE20070427A1 (es) 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
CA2643066A1 (en) 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
CN101415411A (zh) 2006-04-05 2009-04-22 诺瓦提斯公司 用于治疗癌症的治疗剂组合
US7501430B2 (en) * 2006-04-17 2009-03-10 Arqule, Inc. RAF inhibitors and their uses
SG174772A1 (en) 2006-09-11 2011-10-28 Curis Inc Multi-functional small molecules as anti-proliferative agents
JP2010503717A (ja) 2006-09-18 2010-02-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｅｇｆｒ変異を有する腫瘍を治療するための方法
BRPI0719797A8 (pt) 2006-10-02 2017-12-26 Novartis Ag Compostos e composições como inibidores de proteína cinase
US20100087464A1 (en) * 2006-10-06 2010-04-08 Irm Llc Protein kinase inhibitors and methods for using thereof
PE20090519A1 (es) 2007-02-15 2009-05-29 Novartis Ag Composicion farmaceutica que contiene n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)-etil]-amino]-metil]-fenil]-2e-2-propenamida
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
BRPI0815042A2 (pt) 2007-08-01 2015-02-10 Pfizer Compostos de pirazol
PA8800101A1 (es) 2007-10-19 2009-05-15 Abbott Gmbh & Co Kg Producto de dispersion sólida que contiene un compuesto a base de n-aril urea
RU2492170C9 (ru) * 2007-11-14 2013-12-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
WO2009115572A2 (en) * 2008-03-21 2009-09-24 Novartis Ag Novel heterocyclic compounds and uses therof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CN102105459B (zh) 2008-07-24 2014-09-10 内尔维阿诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑类
EP2326622A1 (en) 2008-07-28 2011-06-01 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
KR20110063574A (ko) 2008-09-29 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 항증식성 화합물
UA106878C2 (uk) 2008-10-07 2014-10-27 Астразенека Юк Лімітед Фармацевтична композиція, що містить 4-[3-(4-циклопропанкарбонілпіперазин-1-карбоніл)-4-фторбензил]-2н-фталазин-1-он або його сіль, або сольват, у твердій дисперсії з матричним полімером коповідоном
WO2010056662A1 (en) * 2008-11-11 2010-05-20 University Of Washington Activated wnt-beta-catenin signaling in melanoma
EP2373664B1 (en) 2008-12-19 2013-06-12 Nerviano Medical Sciences S.r.l. Bicyclic pyrazoles as protein kinase inhibitors
AR075180A1 (es) 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
RU2402602C1 (ru) 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2010100127A1 (en) * 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
JP5789602B2 (ja) * 2009-06-15 2015-10-07 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ピリミジニルピロロピリジノン誘導体、これらの製造のための方法およびキナーゼ阻害剤としてのこれらの使用
KR101256018B1 (ko) * 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
US8242260B2 (en) * 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
EA023942B1 (ru) 2010-01-27 2016-07-29 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Сульфонамидные производные 3,4-диарилпиразолов в качестве ингибиторов протеинкиназы
MX355038B (es) 2010-03-30 2018-03-28 Verseon Corp Compuestos aromáticos multisustituidos como inhibidores de trombina.
CN103153980B (zh) 2010-08-03 2015-12-16 内尔维安诺医学科学有限公司 吡唑并苯基苯磺酰胺化合物的衍生物及其作为抗肿瘤药的用途
US20140093565A1 (en) 2011-03-21 2014-04-03 Valcuria Ab A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof
AU2012271814A1 (en) 2011-06-14 2013-12-12 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
MY172729A (en) 2011-11-23 2019-12-11 Array Biopharma Inc Pharmaceutical formulations
AU2013343425A1 (en) 2012-11-08 2015-06-11 Novartis Ag Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
US10576680B2 (en) 2015-11-19 2020-03-03 The Boeing Company Modular thermoforming system

Also Published As

Publication number Publication date
SG10201405311TA (en) 2014-09-26
CR20120102A (es) 2012-05-02
ES2610825T3 (es) 2017-05-03
LUC00101I1 (me) 2019-02-13
SMT201700036T1 (it) 2017-03-08
US20230116233A1 (en) 2023-04-13
JO3002B1 (ar) 2016-09-05
CN103896921A (zh) 2014-07-02
CN102725283B (zh) 2014-02-26
ES2492499T3 (es) 2014-09-09
ME01860B (me) 2014-12-20
CA2771775A1 (en) 2011-03-03
CL2012000340A1 (es) 2012-08-17
HN2012000441A (es) 2015-01-05
AU2010286569A1 (en) 2012-04-12
CU24110B1 (es) 2015-07-30
GEP20146102B (en) 2014-05-27
LUC00101I2 (me) 2020-01-23
JP2013503186A (ja) 2013-01-31
HRP20140799T1 (hr) 2014-11-07
JP2014098022A (ja) 2014-05-29
US9593099B2 (en) 2017-03-14
BR112012004453A8 (pt) 2021-06-08
JP5475888B2 (ja) 2014-04-16
LUC00102I2 (me) 2024-05-21
ECSP12011700A (es) 2012-03-30
SMT201400133B (it) 2014-11-10
PE20120861A1 (es) 2012-07-14
HK1167390A1 (en) 2012-11-30
CN103896921B (zh) 2016-02-24
NO2019012I1 (no) 2019-03-05
US9593100B2 (en) 2017-03-14
CY2019013I2 (el) 2019-11-27
BR112012004453B1 (pt) 2022-04-26
AR077975A1 (es) 2011-10-05
US10576080B2 (en) 2020-03-03
PL2727918T3 (pl) 2017-06-30
AU2010286569C1 (en) 2019-11-28
USRE49556E1 (en) 2023-06-20
HUS1900013I1 (hu) 2019-04-29
EA201200373A1 (ru) 2012-09-28
CY2019014I2 (el) 2019-11-27
US8501758B2 (en) 2013-08-06
DK2470526T3 (da) 2014-08-25
SMT201700036B (it) 2017-03-08
LTC2470526I2 (lt) 2020-04-27
PT2727918T (pt) 2017-01-20
IL218084A0 (en) 2012-04-30
BR112012004453A2 (pt) 2021-03-09
NI201200029A (es) 2012-05-29
NL300973I2 (nl) 2022-05-05
CO6612222A2 (es) 2013-02-01
GT201200053A (es) 2014-03-27
US10005761B2 (en) 2018-06-26
LTPA2019005I1 (lt) 2019-03-25
RS55568B1 (sr) 2017-05-31
US20160122324A1 (en) 2016-05-05
CU20120034A7 (es) 2012-06-21
WO2011025927A1 (en) 2011-03-03
US9850229B2 (en) 2017-12-26
EP2470526A1 (en) 2012-07-04
US20180297986A1 (en) 2018-10-18
US20180297985A1 (en) 2018-10-18
EA025222B1 (ru) 2016-12-30
US20200323852A1 (en) 2020-10-15
UA112285C2 (uk) 2016-08-25
HUE032847T2 (hu) 2017-11-28
CA2771775C (en) 2015-01-20
US20160280686A1 (en) 2016-09-29
PT2470526E (pt) 2014-09-01
LTPA2019006I1 (lt) 2019-03-25
US20110306625A1 (en) 2011-12-15
JP6045519B2 (ja) 2016-12-14
PL2470526T3 (pl) 2014-10-31
DK2727918T3 (da) 2017-01-23
NL300973I1 (me) 2019-03-27
NZ598924A (en) 2013-07-26
UY32860A (es) 2011-03-31
EP2727918A1 (en) 2014-05-07
US20130296318A1 (en) 2013-11-07
US20160280687A1 (en) 2016-09-29
SI2727918T1 (sl) 2017-02-28
TN2012000081A1 (en) 2013-09-19
US9850230B2 (en) 2017-12-26
ZA201202020B (en) 2012-12-27
MY156259A (en) 2016-01-29
ME02684B (me) 2017-06-20
CY2019013I1 (el) 2019-11-27
IN2012DN02469A (me) 2015-08-21
CN102725283A (zh) 2012-10-10
US9314464B2 (en) 2016-04-19
SI2470526T1 (sl) 2014-09-30
RS53489B1 (en) 2015-02-27
AU2010286569B2 (en) 2013-10-10
ECSP23004573A (es) 2023-04-28
KR101413392B1 (ko) 2014-06-27
KR20120062839A (ko) 2012-06-14
US10568884B2 (en) 2020-02-25
EP2470526B1 (en) 2014-05-28
SG178351A1 (en) 2012-03-29
NO2019011I1 (no) 2019-03-05
CY2019014I1 (el) 2019-11-27
LT2727918T (lt) 2017-01-25
CY1118452T1 (el) 2017-07-12
US20160120866A1 (en) 2016-05-05
IL218084A (en) 2016-11-30
HRP20170005T1 (hr) 2017-03-10
EA201500175A1 (ru) 2015-05-29
MX2012002546A (es) 2012-04-11
US20160263113A1 (en) 2016-09-15
HUS1900012I1 (hu) 2019-04-29
EP2727918B1 (en) 2016-10-12
DOP2012000051A (es) 2012-05-31

Similar Documents

Publication Publication Date Title
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
MA34969B1 (fr) Composes et compositions en tant qu inibiteurs de trk
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MA28435B1 (fr) Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4
MA47447A (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA34474B1 (fr) Agonistes de gpr40
MA30462B1 (fr) Composes de pyridylamide antagonistes des canaux calciques de type t
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
BRPI0409173A (pt) compostos e composições como inibidores de proteìna quinase
MA33593B1 (fr) Composés hétérocycliques et leurs utilisations
MA41179A (fr) Composés inhibiteurs de parg
TW200612926A (en) Compounds and compositions as ppar modulators
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
TNSN07258A1 (fr) Derives de quinoleine heteroaromatiques et leur utilisation comme inhibiteurs de pde10
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
MA33730B1 (fr) Procédés de synthèse pour des composés spiro-oxindoles
MA31707B1 (fr) Dérivés de benzimidazole et d'indole substitués par de l'oxadiazole et oxazole comme inhibiteurs de dgat1
MA33241B1 (fr) Composes pour le traitement de troubles metaboliques
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex